She makes the case for why two antigens should naturally be better than one. Lyell is moving into a pivotal study, and will even be doing a head-to-head study against existing commercial CD19 CAR-T products. Plus, why the company acquired a new CAR-T program for colorectal cancer. Coverage brought to you by

On the heels of a historic recent approval for the class, Lynn Seely describes the science behind TIL therapies.